Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma

Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the most frequent liver cancer with high lethality and low five-year survival rates leading to a substantial worldwide burden for healthcare systems. HCC initiation and progression are favored by different etiological risk factors including hepatitis B virus (HBV) a...

Full description

Bibliographic Details
Main Authors:	Deniz Tümen, Philipp Heumann, Karsten Gülow, Cagla-Nur Demirci, Lidia-Sabina Cosma, Martina Müller, Arne Kandulski
Format:	Article
Language:	English
Published:	MDPI AG 2022-12-01
Series:	Biomedicines
Subjects:	HCC NAFLD NASH non-alcoholic fatty liver disease non-alcoholic steatohepatitis lenvatinib
Online Access:	https://www.mdpi.com/2227-9059/10/12/3202

Similar Items

S100 Proteins in Fatty Liver Disease and Hepatocellular Carcinoma
by: Etienne Delangre, et al.
Published: (2022-09-01)

NON-ALCOHOLIC FATTY LIVER DISEASE OUTCOMES FUNNEL
by: D. V. Blinov
Published: (2015-12-01)

A case of metabolic syndrome, positive antinuclear antibodies and cirrhosis.
by: Alessandro Grasso
Published: (2007-09-01)

Preventative and Therapeutic Effects of Astaxanthin on NAFLD
by: Nor Hafiza Sayuti, et al.
Published: (2023-08-01)

Unraveling the Role of Leptin in Liver Function and Its Relationship with Liver Diseases
by: Maite Martínez-Uña, et al.
Published: (2020-12-01)

Fibrosis-4 index is associated with the risk of hepatocellular carcinoma in patients with cirrhosis and nonalcoholic steatohepatitis
by: Somaya Albhaisi, et al.
Published: (2023-08-01)

Research progress of drugs targeting ferroptosis for the treatment of non-alcoholic fatty liver disease
by: HAO Dandan, ZHANG Lei, BAI Chunying
Published: (2023-08-01)

Genetic and Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD) Research
by: Christina-Maria Flessa, et al.
Published: (2022-12-01)

The Effect of Vitamin E Supplementation on Serum Aminotransferases in Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review and Meta-Analysis
by: Stamatina Vogli, et al.
Published: (2023-08-01)

Loss of hepatic VMP1 trapped VLDL in the bilayer of endoplasmic reticulum membrane
by: Hong-Min Ni, et al.
Published: (2023-06-01)

Insulin treatment improves liver histopathology and decreases expression of inflammatory and fibrogenic genes in a hyperglycemic, dyslipidemic hamster model of NAFLD
by: Victoria Svop Jensen, et al.
Published: (2021-02-01)

Exercise Attenuates the Transition from Fatty Liver to Steatohepatitis and Reduces Tumor Formation in Mice
by: Maria Guarino, et al.
Published: (2020-05-01)

Involvement of a periodontal pathogen, <it>Porphyromonas gingivalis </it>on the pathogenesis of non-alcoholic fatty liver disease
by: Yoneda Masato, et al.
Published: (2012-02-01)

The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review
by: Rodrigo Zamignan Carpi, et al.
Published: (2022-08-01)

Utilization of Food-Derived β-Glucans to Prevent and Treat Non-Alcoholic Fatty Liver Disease (NAFLD)
by: Nelson Kei, et al.
Published: (2023-09-01)

Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD)
by: Christoph Roderburg, et al.
Published: (2023-04-01)

PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN REPUBLIC OF BASHKORTOSTAN (REGIONAL RESULTS OF DIREG 2 STUDY)
by: D. Kh. Kalimullina, et al.
Published: (2017-03-01)

EPIDEMIOLOGICAL FEATURES OF NON-ALCOHOLIC FATTY LIVER DISEASE IN NOVOSIBIRSK (SIBERIAN FEDERAL DISTRICT): REGIONAL DATA OF OPEN MULTICENTER PROSPECTIVE STUDY DIREG 2
by: V. V. Tsukanov, et al.
Published: (2016-09-01)

Caspase-11 promotes high-fat diet-induced NAFLD by increasing glycolysis, OXPHOS, and pyroptosis in macrophages
by: Charles Drummer, et al.
Published: (2023-01-01)

Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis
by: Nicha Wongjarupong, et al.
Published: (2017-12-01)

NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs
by: Stephen Caldwell
Published: (2017-06-01)

RISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
by: Lourianne Nascimento CAVALCANTE, et al.
Published: (2022-11-01)

Research landscape and frontiers of non-alcoholic steatohepatitis-associated hepatocellular carcinoma: a bibliometric and visual analysis
by: Bowen Gao, et al.
Published: (2023-09-01)

Presence and Implications of Sarcopenia in Non-alcoholic Steatohepatitis
by: Gregory Habig, et al.
Published: (2021-04-01)

SIRT2 Deficiency Aggravates Diet-Induced Nonalcoholic Fatty Liver Disease through Modulating Gut Microbiota and Metabolites
by: Xingyu Li, et al.
Published: (2023-05-01)

Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants
by: Clémence Rives, et al.
Published: (2020-12-01)

Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes
by: Alessandro Mantovani, et al.
Published: (2022-02-01)

Heterogeneous population of macrophages in the development of non-alcoholic fatty liver disease
by: Ye Eun Cho, et al.
Published: (2023-03-01)

Effects of Synbiotics, Probiotics, and Prebiotics on Liver Enzymes of Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis
by: Sukrit Kanchanasurakit, et al.
Published: (2022-05-01)

Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease
by: Yang Xiao, et al.
Published: (2021-08-01)

NASH and cryptogenic cirrhosis: A histological analysis†† Financial Support/Grants: This research supported in part by the Intramural Research Program of the NIH, National Cancer Institute.
by: Stephen H. Caldwell, et al.
Published: (2009-10-01)

Role of B Lymphocytes in the Pathogenesis of NAFLD: A 2022 Update
by: Chu-Jun Deng, et al.
Published: (2022-10-01)

Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
by: Martina Colognesi, et al.
Published: (2020-07-01)

PNPLA3(I148M) Inhibits Lipolysis by Perilipin-5-Dependent Competition with ATGL
by: Hagen Roland Witzel, et al.
Published: (2022-12-01)

Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena
by: Aamir Bashir, et al.
Published: (2022-06-01)

Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
by: Hyunmi Kim, et al.
Published: (2021-04-01)

Can Walnut Serve as a Magic Bullet for the Management of Non-Alcoholic Fatty Liver Disease?
by: Mi-Young Kim, et al.
Published: (2020-12-01)

MAFLD and CKD: An Updated Narrative Review
by: Alessandro Mantovani, et al.
Published: (2022-06-01)

Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients
by: Yan Huang, et al.
Published: (2022-01-01)

Oxidized Lipids: Common Immunogenic Drivers of Non-Alcoholic Fatty Liver Disease and Atherosclerosis
by: Constanze Hoebinger, et al.
Published: (2022-01-01)